101 related articles for article (PubMed ID: 10505300)
1. Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.
Mück W; Ochmann K; Mazzu A; Lettieri J
J Int Med Res; 1999; 27(3):107-14. PubMed ID: 10505300
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening.
Mück W; Frey R; Unger S; Voith B
Int J Clin Pharmacol Ther; 2000 Jun; 38(6):298-303. PubMed ID: 10890578
[TBL] [Abstract][Full Text] [Related]
3. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
[TBL] [Abstract][Full Text] [Related]
4. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Ochmann K; Rohde G; Unger S; Kuhlmann J
Eur J Clin Pharmacol; 1998 Feb; 53(6):469-73. PubMed ID: 9551706
[TBL] [Abstract][Full Text] [Related]
5. Influence of cholestyramine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Frey R; Wetzelsberger N; Lücker PW; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):250-4. PubMed ID: 9208341
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of cerivastatin.
Mück W
Clin Pharmacokinet; 2000 Aug; 39(2):99-116. PubMed ID: 10976657
[TBL] [Abstract][Full Text] [Related]
7. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
Weber P; Lettieri JT; Kaiser L; Mazzu AL
Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
[TBL] [Abstract][Full Text] [Related]
8. Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers.
Mazzu A; Lettieri J; Kaiser L; Mullican W; Heller AH
J Clin Pharmacol; 1998 Aug; 38(8):715-9. PubMed ID: 9725547
[TBL] [Abstract][Full Text] [Related]
9. Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.
Mazzu AL; Lettieri JT; Kelly E; Vargas R; Marbury T; Liu MC; Sundaresan P
Eur J Clin Pharmacol; 2000 Apr; 56(1):69-74. PubMed ID: 10853881
[TBL] [Abstract][Full Text] [Related]
10. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.
Renders L; Haas CS; Liebelt J; Oberbarnscheidt M; Schöcklmann HO; Kunzendorf U
Br J Clin Pharmacol; 2003 Aug; 56(2):214-9. PubMed ID: 12895195
[TBL] [Abstract][Full Text] [Related]
12. Effect of itraconazole on cerivastatin pharmacokinetics.
Kantola T; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 1999 Jan; 54(11):851-5. PubMed ID: 10027660
[TBL] [Abstract][Full Text] [Related]
13. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
[TBL] [Abstract][Full Text] [Related]
14. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
15. Lack of drug-drug interaction between cerivastatin and nifedipine.
Sachse R; Brendel E; Mück W; Rohde G; Ochmann K; Horstmann R; Kuhlmann J
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):409-13. PubMed ID: 9726692
[TBL] [Abstract][Full Text] [Related]
16. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
Mück W; Unger S; Kawano K; Ahr G
Br J Clin Pharmacol; 1998 Jun; 45(6):583-90. PubMed ID: 9663814
[TBL] [Abstract][Full Text] [Related]
17. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
Mück W; Mai I; Fritsche L; Ochmann K; Rohde G; Unger S; Johne A; Bauer S; Budde K; Roots I; Neumayer HH; Kuhlmann J
Clin Pharmacol Ther; 1999 Mar; 65(3):251-61. PubMed ID: 10096257
[TBL] [Abstract][Full Text] [Related]
18. Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.
Isaacsohn J; Zinny M; Mazzu A; Lettieri J; Heller AH
Eur J Clin Pharmacol; 2001 Mar; 56(12):897-903. PubMed ID: 11317478
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance.
Vormfelde SV; Mück W; Freudenthaler SM; Heyen P; Schmage N; Kuhlmann J; Müller GA; Gundert-Remy UM; Gleiter CH
J Clin Pharmacol; 1999 Feb; 39(2):147-54. PubMed ID: 11563406
[TBL] [Abstract][Full Text] [Related]
20. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia.
Stein E; Sprecher D; Allenby KS; Tosiello RL; Whalen E; Ripa SR
J Cardiovasc Pharmacol Ther; 1997 Jan; 2(1):7-16. PubMed ID: 10684437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
